Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Paclitaxel
Drug ID BADD_D01653
Description Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
Indications and Usage Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
Marketing Status approved; vet_approved
ATC Code L01CD01
DrugBank ID DB01229
KEGG ID D00491
MeSH ID D017239
PubChem ID 36314
TTD Drug ID D0C4RB
NDC Product Code 0703-3213; 52222-0001; 65129-1308; 68083-179; 69539-159; 62422-0004; 68001-516; 68083-178; 0703-4768; 68554-0061; 46708-622; 47781-595; 62332-621; 62332-622; 63323-763; 72205-063; 60505-6230; 62332-620; 72205-062; 0517-4300; 0703-3216; 0703-3218; 17359-3055; 63126-902; 69539-158; 72205-061; 17359-4056; 49452-4961; 51446-0110; 59651-605; 0703-4764; 51446-0120; 46708-620; 61703-342; 68083-180; 0703-3217; 17359-4040; 62422-0002; 69539-157; 70860-215; 42533-111; 54893-0007; 65129-2039; 69443-022; 16714-137; 68817-134; 70860-200; 17359-4055; 65892-002; 24979-710; 46708-621
UNII P88XT4IS4D
Synonyms Paclitaxel | Anzatax | NSC-125973 | NSC 125973 | NSC125973 | Taxol | Taxol A | Bris Taxol | Taxol, Bris | Paclitaxel, (4 alpha)-Isomer | Paxene | Praxel | 7-epi-Taxol | 7 epi Taxol | Onxol
Chemical Information
Molecular Formula C47H51NO14
CAS Registry Number 33069-62-4
SMILES CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6) O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Depressed level of consciousness17.02.04.0020.001063%
Depressed mood19.15.02.001--Not Available
Depression19.15.01.001--
Dermatitis23.03.04.0020.000470%Not Available
Dermatitis atopic10.01.04.004; 23.03.04.016--Not Available
Dermatitis bullous23.03.01.0020.000336%
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Dermatomyositis10.04.04.027; 23.03.02.001; 15.05.01.0020.000280%Not Available
Diarrhoea07.02.01.001--
Diarrhoea haemorrhagic24.07.02.004; 07.02.01.0020.000280%Not Available
Dilatation ventricular02.04.02.0260.000112%Not Available
Diplopia17.17.01.005; 06.02.06.0020.000392%Not Available
Discomfort08.01.08.003--Not Available
Disinhibition19.05.01.0020.000112%Not Available
Disseminated intravascular coagulation24.01.01.010; 01.01.02.0020.000839%
Dissociative disorder19.14.01.0030.000224%Not Available
Dizziness17.02.05.003; 02.11.04.006; 24.06.02.007--
Dizziness postural02.11.04.008; 24.06.02.008; 17.02.05.004--Not Available
Drug hypersensitivity10.01.01.001--Not Available
Drug interaction08.06.03.001--Not Available
Dry eye06.08.02.001--
Dry mouth07.06.01.002--
Dry skin23.03.03.001--
Dry throat22.12.03.005; 07.06.01.0050.000224%Not Available
Dysaesthesia23.03.03.077; 17.02.06.0030.000728%
Dysgeusia17.02.07.003; 07.14.03.001--
Dyskinesia17.01.02.006--
Dysmetria17.02.02.0050.000168%Not Available
Dyspepsia07.01.02.001--
Dysphagia07.01.06.003--
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 27 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene